1. Vaccine for ‘flesh-eating’ deadly bacteria in the offing

Vaccine for ‘flesh-eating’ deadly bacteria in the offing

Scientists led by an Indian origin biochemist are working on a vaccine against a highly infectious bacteria responsible for more than 500,000 deaths a year.

By: | Los Angeles | Published: September 6, 2016 2:45 PM
Scientists led by an Indian origin biochemist are working on a vaccine against a highly infectious bacteria responsible for more than 500,000 deaths a year. (FE photo) Scientists led by an Indian origin biochemist are working on a vaccine against a highly infectious bacteria responsible for more than 500,000 deaths a year. (FE photo)

Scientists led by an Indian origin biochemist are working on a vaccine against a highly infectious bacteria responsible for more than 500,000 deaths a year. Biochemists at the University of California San Diego in the US have uncovered patterns in the outer protein coat of group A Streptococcus that could finally lead to a vaccine against the bacteria that causes toxic shock syndrome and necrotising fasciitis or “flesh-eating disease.”

The researchers uncovered “hidden sequence patterns in the major surface protein and virulence factor” of group A Strep, called the M protein, that limit the body’s immune response against these bacteria.

“At present, there is no vaccine against group A Strep, and our discovery of hidden sequence patterns has offered up a novel way to devise such a vaccine,” said Partho Ghosh, chair of UC San Diego’s Department of Chemistry and Biochemistry, who headed the research.

Ghosh said that one of the biggest obstacles to the development of a vaccine against these bacteria is the “hyper-variability” of the M protein. Group A Strep bacteria have a multitude of different strains, each of which displays a different protein on its surface.

Because our immune systems must recognise these different proteins before launching an immune response with antibodies specific to the outer protein coat, the hyper-variability of the M proteins make it difficult for our immune systems to attach antibodies specific to each these proteins from different strains.

The key to resolving the problem was the recognition that a human protein called C4BP is recruited to the surface of group A Strep by many different protein types.

“This was a puzzle, because the antibody response is specific and limited to a single M protein type, while C4BP binds a broad variety of M protein types, perhaps up to 90 per cent of them,” said Ghosh.

“Group A Strep brings C4BP to its surface to dampen the immune response. We wanted to combat this recruitment by blocking the interaction between M proteins and C4BP, but equally as importantly, we wanted to take advantage of the broad recruitment of C4BP by M proteins that would pave a path to the development of a vaccine,” he said.

“The idea now is to have antibodies do the same thing as C4BP – that is, recognise many different M protein types,” Ghosh said.

“That way, the antibody response will not be limited to one M protein type and one strain of group A Strep, but will extend to most, if not all, M protein types and most, if not all strains, of group A Strep,” he added.
The researchers are now working on developing a vaccine that, they hope, will be protective against most, if not all, strains of group A Strep.

The research was published in the journal Nature Microbiology.

Get latest news and updates on Auto Expo 2018, check breaking news on Budget 2018, like us on Facebook and follow us on Twitter.

  1. No Comments.

Go to Top